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ABSTRACT 
 
Beneficial Effects of Dietary L-Arginine Supplementation  
to Diabetic Rats. (August 2003) 
Ripla Kohli, B.H.S., University of Delhi; M.S., Shreemati Nathibai Damodar  
Thackersey Women’s University   
                    Chair of Advisory Committee: Dr. Guoyao Wu 
 
 
 
Diabetic rats exhibit decrease in plasma arginine, NO synthesis and 
tetrahydrobiopterin in endothelial cells (EC). Treatment with L-arginine may be 
beneficial for enhancing NO synthesis in diseases associated with endothelial 
dysfunction. However, little is known about the mechanism responsible for the 
stimulatory effect of arginine on endothelial NO synthesis. We hypothesized that dietary 
arginine supplementation increases BH4 for NO synthesis in EC of diabetic rats, thereby 
preventing endothelial dysfunction. In experiment I, streptozotocin (STZ) induced-
diabetic male Sprague Dawley (SD) rats (a model of type-I diabetes) were individually 
pair- fed a casein-based diet on the basis of feed intake (per kg body weight) of non-
diabetic SD rats. Addition of arginine-HCl or alanine to drinking water for the rats were 
adjusted daily to ensure isonitrogenous provision per kg body weight. In non-diabetic 
rats, arginine supplementation increased plasma arginine (144%), plasma insulin (44%), 
and arginine concentrations (88%), BH4 concentrations (106%) and NO synthesis (80%) 
in EC, compared with alanine treatment. In diabetic rats, arginine supplementation 
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reduced body weight loss (36%), and plasma glucose (54%), and increased plasma 
arginine (110%), plasma insulin (209%), EC arginine (173%), EC BH4 (128%) and EC 
NO synthesis (125%), compared with alanine treatment.  In experiment II, male Zucker 
diabetic fatty (ZDF) rats (a model of type-II diabetes) were individually pair-fed a Purina 
5008 diet on the basis of feed intake by alanine-treated diabetic rats (per kg body wt). 
Addition of arginine-HCl or alanine to drinking water for the rats was adjusted daily to 
ensure isonitrogenous provision per kg body weight. Arginine supplementation to ZDF 
rats did not affect plasma levels of glucose and insulin, reduced epidididmal fat (30%), 
abdominal fat (43%) and body weight gain (18%), and increased plasma arginine 
(273%), EC arginine (197%), EC BH4 (120%) and EC NO synthesis (122%), compared 
with alanine-treated ZDF rats. These results show that dietary L-arginine 
supplementation increases BH4 and NO synthesis in EC of both STZ-diabetic and ZDF 
rats. Strikingly, arginine treatment prevented hyperglycemia in STZ-diabetic SD rats and 
reduced obesity in ZDF rats. Collectively, results demonstrate that oral administration of 
arginine is beneficial for both type-I and type-II diabetic rats. 
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CHAPTER I 
INTRODUCTION 
 
Introduction 
Diabetes mellitus is a group of metabolic diseases characterized by 
hyperglycemia resulting from defects in insulin secretion, insulin action, or both (1). 
Vascular complications are the major cause of morbidity and mortality in patients with 
diabetes (2, 3). Diabetic patients are at considerable risk of cardiovascular, 
cerebrovascular and peripheral vascular disease leading to myocardial infarction, 
strokes, and amputations (4). It is estimated that 77% of hospitalizations in the United 
States for chronic complications of diabetes are attributable to cardiovascular disease 
(CVD) (5). 
Multiple factors contribute to the macrovascular abnormalities in diabetes, 
manifested by accelerated atherosclerosis (6). These factors include oxidation and 
glycation of proteins and prevalence of traditional risks such as obesity, hypertension, 
and dyslipidemia, and the state of insulin resistance (5). Furthermore, small-vessel 
disease, resulting in diabetic retinopathy and nephropathy, also contributes importantly 
to the morbidity associated with this disease (6).  
The endothelium lines the entire vascular system and is comprised of a 
monolayer of endothelial cells (EC). In an adult human, the endothelium consist of  
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approximately 1x1013 cells forming an almost 1 kg “tissue” (7). Endothelium plays a key 
role in maintaining homeostasis of the vasculature through the synthesis of vasoactive 
substances that modulate vascular tone, as well as inhibition of platelet aggregation and 
vascular smooth muscle cell (VSMC) proliferation (8). Loss of the modulatory role of 
the endothelium could be implicated in the pathogenesis of the diabetic vascular 
complications.  
Endothelial dysfunction in diabetes. There is now substantial evidence 
indicating that endothelial dysfunction, characterized by diminished endothelium-
dependent relaxation, is abnormal in experimental models of diabetes mellitus 
(9,10,11,12,13). Several other studies have also demonstrated impaired endothelium-
dependent vasodilation in human diabetic patients (14,15). Studies designed to 
investigate the mechanism of this dysfunction have implicated the involvement of 
various factors. These factors include (1) destruction of endothelium by oxygen-derived 
free radicals (16); (2) increased release of endothelium-derived constricting factors (17); 
or (3) decreased release or production of nitric oxide (NO) (13,18). Hyperglycemia 
contributes directly to above mentioned factors and thus to endothelial dysfunction. 
There is substantial evidence suggesting that high concentrations of glucose could 
reduce NO availability due to an increase in superoxide anion production (19). Further, 
elevated glucose levels may lead to a decrease in cellular concentrations of nicotinamide 
adenine dinucleotide phosphate (reduced form) (NADPH) through activation of the 
polyol pathway (3). Because NADPH is an essential cofactor for NO synthase (NOS) for 
NO synthesis, its depletion could lead to a reduction in endothelial NO production. 
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Activation of protein kinase C (PKC) induced by hyperglycemia has also been suggested 
as a mechanism for endothelial dysfunction and vascular complications in diabetes (3). 
Additionally, in the presence of high plasma glucose concentrations, circulating or 
intracellular proteins undergo changes in structure and function, resulting in the 
formation of advanced glycation end products (AGE) (3). These AGE may affect 
cellular metabolism and contribute to endothelial dysfunction and diabetic vascular 
complications. 
Although several mechanisms for the defect in diabetic blood vessels have been 
proposed, much attention has been focused on altered endothelial production of NO. 
This free radical molecule is the most potent endothelium-derived vasodilator, and is 
essential for the regulation of vascular tone and integrity. L-Arginine is the substrate for 
the NOS, which is responsible for NO production in the presence of O2, 
tetrahydrobiopterin (BH4), NADPH, FAD, FMN, Ca2+ and calmodulin  (20). Endothelial 
NOS (eNOS) is constitutively expressed in the vasculature. Therefore, endothelial 
dysfunction could be attributed to a deficiency of arginine or a cofactor of NOS, and/or 
to the presence of endogenous inhibitors of NOS. This hypothesis leads to the 
assumption that increased provision of L-arginine could be beneficial for improving 
endothelial function. Thus, in diseases associated with reduced plasma arginine levels,  
NO synthesis may be inadequate and endothelium-dependent relaxation may be 
impaired (21). Several studies have shown that plasma concentrations of arginine are  
decreased in experimental diabetic animals (10,11,12) and in diabetic humans  (21,22). 
Thus, in recent years, there has been growing interest in the use of L-arginine to prevent 
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and treat endothelial dysfunction in diabetes.  However, little is known about the 
mechanism responsible for the stimulatory effect of arginine on endothelial NO 
synthesis in normal or diabetic subjects.  
Arginine availability for endothelial cells. L-Arginine is a basic amino acid 
found in large quantities in fish and other seafood, nuts, meats, and beans. In healthy 
adults, arginine can be synthesized endogenously from citrulline produced from 
glutamine and proline in enterocytes of the small intestine; the major tissue responsible 
for arginine synthesis is the kidney. However, in young animals and in other situations 
characterized by increased arginine requirements (e.g. infection, trauma and sepsis), the 
endogenous synthesis of arginine (primarily in the small intestine and kidney) may not 
be sufficient to meet the demand for this amino acid (23). Approximately 5.4 g of 
arginine is consumed each day in adults who ingest an average US diet (23).  
Endothelial cells form the inner layer of all blood vessels and are in direct 
contact with circulation. EC derive arginine from plasma, intracellular synthesis and 
protein degradation. Homeostasis of plasma arginine concentrations is regulated by 
dietary arginine intake, protein turnover, arginine synthesis and metabolism. This 
explains why arginine becomes an essential dietary component under certain disease 
conditions. Due to a relatively high arginase activity in enterocytes, 40% of dietary 
arginine is degraded during absorption and  the remainder enters the portal vein. 
However, more than 85% of arginine delivered to liver is not taken up by this organ. 
Although, the liver is also capable of synthesizing considerable amounts of arginine, this 
amino acid is rapidly hydrolyzed by arginase via the urea cycle. Thus, the liver does not 
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contribute to plasma arginine flux (24). The separation between hepatic and systemic 
arginine pools can be attributed to the fact that the active basic amino acid uptake 
system, the y+ transporter, has a very low activity in hepatocytes. Normal plasma 
arginine concentrations in humans and animals range from 95 to 250 µM. Although 
extracellular arginine is the major source of the arginine for endothelial NO synthesis 
(20), EC are able to recycle citrulline (a product of NO synthesis) into arginine via the 
so-called arginine–citrulline cycle (24). 
NO-dependent effects of arginine. The vascular effects of arginine are mediated 
primarily by NO production (20,25). The discovery of endothelial NO synthesis in late 
1980’s (26) has considerably improved our understanding of vascular biology and 
pathophysiology. NO mediates the endothelium-dependent vasodilation in response to 
stimuli such as shear stress, insulin, and actylcholine (27). Recent evidence suggests that 
NO interacts with other flow-induced vasodilation mediators, including prostacyclin and 
adenosine, and this interaction results in net hemodynamic changes. NO has also been 
shown to mediate exercise- induced vasodilation (28). As a potent endogenous 
vasodilator, NO has numerous beneficial effects that preserve normal vascular function. 
For example, NO activates guanylate cyclase in vascular smooth muscle, and increases 
the production of cyclic guanosine monophosphate (cGMP). cGMP, as a second 
messenger, mediates many of the biological effects of NO, e.g. causing relaxation of 
smooth muscle and inhibiting platelet aggregation  (20,28). In addition, NO inhibits 
platelet activation and adhesion to the surface of endothelium, the release of 
vasoconstrictor endothelin-1, smooth muscle cell proliferation, and the synthesis and 
   
 
6 
 
 
 
 
expression of cytokines and cell adhesion molecules that attract monocytes and 
leukocytes to the endothelial surface. NO reduces vascular oxidative stress and inhibits 
superoxide generation (23,29). In addition, NO stimulates angiogenesis, which plays an 
important role in wound healing, vascular remodeling, and conditions like myocardial 
infarction and diabetic retinopathy (23). NO is also a mediator of the immune response, 
a neurotransmitter, a cytotoxic free radical and a widespread signaling molecule (23,25).  
Nisoli et al (30) recently reported that the NO-cGMP-dependent pathway 
controls mitochondrial biogenesis and body energy balance. For example, NOS null-
mutant mice had a reduced metabolic rate and accelerated weight gain (30), insulin 
resistance (27), hypertension, and hyperlipidemia (31). NO stimulates insulin release 
from pancreatic ß cells in the presence of glucose (32). These properties suggest that the 
level of NO production by the endothelium may play a pivotal role in the regulation of 
vascular disease. Therefore, impaired endothelial NO production may constitute a 
critical manifestation of proatherogenic events in the vascular wall, including increased 
vascular tone, platelet aggregation, endothelial barrier dysfunction, vascular 
inflammation, and smooth muscle cell proliferation. Because one of the factors which 
regulate NO production, is arginine availability, utilization of L-arginine and its 
conversion to NO have important implications for the development of endothelial 
dysfunction.  
The arginine paradox. The available evidence indicates that supplemental 
administration of L-arginine is beneficial to restore endothelium-derived NO production 
in many cardiovascular disorders. However, some studies have also revealed that 
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elevating plasma arginine levels may not increase vascular NO synthesis in certain 
diseases (33). These results suggest the complexity of regulation of endothelial NO 
synthesis. The Km value is defined as the substrate concentration at which the reaction 
velocity is half maximal. The Km value of eNOS for L-arginine is 2.9 mM, while the 
intracellular value of L-arginine in vivo is 1-2 mM (20), which sufficiently saturates 
NOS. Thus, from an enzyme biochemical viewpoint, it is argued that additional L-
arginine could not have any effect on NOS activity, because this enzyme should be 
saturated with substrate at physiological levels. However, supplementation of L-arginine 
has consistently been shown to exert a beneficial effect on the endothelium-dependent 
vasodilation in vivo. The so-called arginine paradox remains to be explained.  
NO-independent effects of arginine. In addition to being the precursor of NO 
and an important component of protein, L-arginine is involved in several biologically 
important metabolic pathways (Fig. 1.1). Serving as a precursor for the synthesis of urea, 
creatine, agmatine, proline, polyamines, and glutamate, arginine plays a vital role in the 
physiology of the organism (23). The high energy phosphate storage compound creatine 
is essential for sustained skeletal muscle contraction and for energy metabolism in the 
nervous tissue. Arginine degradation by arginine decarboxylase yields agmatine, which 
is known to interact with receptors that are normally bound by centrally acting 
hypertensive agent including clonidine. L-Arginine is an essential component of the urea 
cycle, the major pathway for elimination of ammonia in mammals (23).  
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FIGURE 1.1 Pathways of arginine catabolism. Enzymes that catalyse the 
indicated reactions are: 1, arginase; 2, NOS; 3, arginine decarboxylase; 4, 
arginine:glycine amidinotransferase; 5, guanidinoacetate N-methyltransferase; 6, 
Ornithine aminotrasferase; 7, Pyrroline-5-carboxylate reductase; 8, Spontaneous 
reaction; 9, Pyrroline-5-carboxylate dehydrogenase; 10, glutamate dehydrogenase; 11, 
alanine aminotransferase, aspartate aminotransferase or branched-chain amino acid 
aminotransferase; 13, glutamine synthetase; 14, glutaminase; 15, ornithine 
decarboxylase; 16, spermidine synthase; 17, spermine synthase. Step 8 is a spontaneous, 
non-enzymic reaction. Abbreviations: DCAM, decarboxylated S-adenosylmethionine; 
MTA, methylthioadenosine; SAM, S-adenosylmethionine; SAHC, S-
adenosylhomocysteine; BH4, (6R)-5,6,7,8-tetrahydro-L-biopterin. 
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Arginine plays an important role in wound healing (34). As a product of arginine 
catabolism by arginase, ornithine is a precursor for synthesis of polyamines (putrescine, 
spermidine and spermine) and proline. Polyamines are essential for cell proliferation and 
differentiation. Proline is critical to collagen synthesis and thus extracellular matrix 
formation and vessel remodeling (23). Supplementation of arginine to healthy 
individuals improves matrix synthesis after wounding, whereas an arginine-free diet 
deteriorates healing in rats (35).  
L-Arginine functions as a secretogogue of a number of important hormones. 
High intravenous doses of L-arginine (30 g) have been used to stimulate growth 
hormone secretion in humans.  In addition, arginine increases the release of insulin, 
glucagon, prolactin polypeptide, and adrenal catecholamines (23,36), thus regulating the 
metabolism of protein, amino acids, glucose, and fatty acids. Arginine, independent of 
NO, is known to decrease lipid peroxidation and thus oxidative stress (37,38). 
Furthermore, arginine reduces copper- induced lipid peroxidation, scavenges O2-, and 
inhibits O2- release by EC (20). Through inhibiting the formation of thromboxane B2 and 
the platelet- fibrin complex while enhancing plasmin generation and fibrin degradation,  
arginine stimulates fibrinogenolysis (23). Arginine may directly decrease leukocyte 
adhesion to nonendothelial matrix (39), thereby inhibiting the development of 
atherosclerosis. Further, high concentrations of arginine may decrease blood viscosity at 
low shear rate independent of NOS activity (40), which contributes to improved blood 
flow after intravascular administration of L-arginine.  
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Arginine in diabetes. Diabetes is associated with reduced plasma concentrations 
of arginine (41,42). Thus, dietary supplementation of L-arginine could be beneficial for 
the treatment of endothelial dysfunction in diabetic patients. Ozcelikay et al. (43) 
showed that L-arginine treatment in vivo could prevent diabetes-associated 
abnormalities in vascular function. These results are consistent with the findings of 
Pieper et al. (41,42), which reported that L-arginine supplementation normalized the 
endothelium-dependent relaxation in diabetic aorta by enhancing NO availability and 
restoring the acetylcholine-stimulated cGMP generation.  
In the diabetic state, it is well known that oxidative stress is increased due to 
excessive production of oxygen free radicals and impaired antioxidant defense 
mechanisms. Increasing arginine supply to diabetic rats improved vascular reactivity, 
reduced blood pressure, and normalized lipid peroxidation (43). Further, concentrations 
of malondialdehyde, a product of lipid peroxidation, may be reduced by arginine in 
diabetic patients (38) and diabetic rats (44). 
It is known that hypertension is an independent risk factor for cardiovascular 
mortality in patients with diabetes. Giugliano et al (45) found that intravenous L-arginine 
infusion completely reversed both the increase in blood pressure and the decrease in leg 
blood flow brought about by short-term elevation of plasma glucose levels in healthy 
subjects. This effect of arginine is mediated by the generation of NO. 
As noted previously, AGE contribute to endothelial dysfunction and diabetic 
vascular complications by permanent chemical modification of cells and proteins (3). 
Interestingly, L-arginine supplementation may directly inhibit AGE action on the 
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vasculature (22). Because AGE is believed to quench NO, arginine administration might 
be of benefit to improve the endothelium-dependent relaxation by preventing AGE-
mediated quenching of the NO-dependent smooth muscle relaxation (22).  
Mendez and Balderas (32) recently reported beneficial effects of L-arginine 
supplementation on reducing serum concentrations of glucose and lipids in diabetic rats. 
These authors suggested that the beneficial effects of L-arginine treatment are primarily 
due to the action of polyamines synthesized from the arginine-derived ornithine in 
extrahepatic tissues. Putrescine and spermidine have antilipolytic action and are 
necessary for insulin and protein biosynthesis, whereas spermine depletion affects 
several processes involved in insulin metabolism (32). Importantly, NO stimulates 
glucose uptake and utilization by skeletal muscle (36). These results provide a 
biochemical basis for explaining the beneficial effects of L-arginine on hyperglycemia 
and dyslipidemia in experimental diabetes. 
Diabetic healing is impaired, but the mechanisms are not well understood. High 
blood glucose lowers fibroblast proliferation (46) and affects collagen synthesis. Cross-
linking of collagen fibers is reduced in diabetic subjects (47). Concentrations of growth 
factors, mediators of collagen synthesis, are also low in the wound milieu (48,49) 
probably secondary to the diminished and delayed inflammatory reaction. In diabetes, 
NO synthesis is reduced in the wound milieu and hence, arginine supplementation 
improves wound healing by restoring NO synthesis (50). Conversely, inhibiting wound 
NO formation lowers collagen formation and wound breaking strength (51), and 
decreases wound contraction (52) Alternatively, arginine can be metabolized in wounds 
   
 
13 
 
 
 
 
via arginase to ornithine. Ornithine is the precursor for polyamines and proline. 
Polyamines are essential for cell proliferation, whereas proline is necessary for collagen 
formation. Ornithine supplementation also enhances wound healing, suggesting that at 
least some of the arginine effect could be mediated through ornithine synthesis (23,34). 
Interestingly, iNOS knock-out mice supplemented with L-arginine do not demonstrate 
improved incisional healing, suggesting that the effect of arginine on wound healing 
involves primarily the arginine- iNOS pathway (50). 
Relation between arginine and tetrahydrobiopterin (BH4). BH4 has long been 
recognized as an essential co-factor for all isoforms of the NOS, including eNOS (53). 
Schmidt et al. (54) were the first to demonstrate that an increase in intracellular BH4 
availability due to an increase in its synthesis stimulated NO production by EC. Since 
this initial report, there has been growing interest in the role of BH4 in the therapeutic 
treatment of endothelial dysfunction (55). Meininger et al. (13) reported that EC from 
the spontaneously diabetic BB rat had an impaired ability to produce NO due to the 
deficiency of BH4 and replenishing BH4 levels in the EC from diabetic animals restored 
their ability to make NO and proliferate.  
 Importantly, administration of either BH4 or L-arginine improves endothelial 
function in experimental animals and humans with a variety of major cardiovascular risk 
factors such as diabetes, insulin resistance, smoking, and hypercholesterolemia 
(56,57,58). However, a combination of both L-arginine and BH4 has no additional effect 
on the endothelium-dependent relaxation, compared with either compound alone (59).  
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These findings raise an important question of whether BH4 is deficient in EC of diabetic 
persons and whether arginine stimulates de novo synthesis of endothelial BH4.  
 
Summary 
Endothelial dysfunction is a major factor contributing to the high rates of 
morbidity and mortality in diabetic patients. Impaired NO synthesis from arginine in EC 
plays an important role in the pathogenesis of diabetes-associated cardiovascular 
complications. Recent studies indicate that a deficiency of BH4 is the biochemical basis 
for inadequate generation of NO in EC. Extensive studies demonstrate that arginine 
administration improves endothelial function in humans with type-I or type-II diabetes 
mellitus and in animal models of type-I diabetes. However, the underlying mechanisms 
are not known. Because the Km value of the three isoforms of the NOS for arginine are 
< 10 µM, it is unlikely that increasing extracellular arginine concentrations would 
increase substrate concentrations for the enzymes in mammalian cells. Alternatively, 
arginine may stimulate endothelial BH4 synthesis and therefore increase endothelial BH4 
availability for NO generation. The available evidence indicates that diabetic subjects 
have low levels of plasma arginine, and thus dietary arginine supplementation may 
provide a potentially novel means to increase arginine availability and prevent 
endothelial dysfunction in diabetic subjects. 
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Objectives of This Research 
In view of the above literature review, we hypothesized that dietary arginine 
supplementation increases the availability of BH4 (a critical cofactor for endothelial 
NOS) for endothelial NO synthesis in diabetic rats, thereby preventing endothelial 
dysfunction. The major objective of the author’s thesis research was to test this 
hypothesis with the use of streptozotocin (STZ)- induced diabetic rats and Zucker 
diabetic fatty (ZDF) rats. The specific aims of the investigations were: 
1. To determine the effect of dietary arginine supplementation on body weight loss, EC 
BH4 availability, EC NO synthesis, and plasma glucose concentrations in STZ 
diabetic rats; and  
2. To determine the effect of dietary arginine supplementation on body weight gain, EC 
BH4 availability, EC NO synthesis, and plasma glucose concentrations in ZDF rats.  
 
Significance of This Research 
NO is an important product of arginine catabolism by NOS in virtually all animal 
cells. Although there is a great body of literature regarding the beneficial role of arginine 
in humans and rats with diabetes and endothelial dysfunction, little is known about the 
mechanisms responsible for the stimulating effect of arginine on endothelial NO 
synthesis in normal and diabetic subjects. Elucidating the underlying mechanism(s) will 
help in the design of new means to treat patients with a wide array of cardiovascular 
disorders. As arginine may be a potentially novel nutrient to improve endothelial 
function, it is of crucial importance to demonstrate that dietary arginine supplementation 
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increases NO synthesis in EC of both normal and diabetic animals. This new knowledge 
about arginine biochemistry and nutrition in the cardiovascular system will provide a 
much-needed experimental basis for the clinical application of arginine to prevent 
endothelial dysfunction in diabetic patients Because obesity and diabetes have become a 
major public health problem in the U.S. and worldwide, arginine may provide an 
effective solution for improving life quality and health of obese and diabetic patients 
while reducing the tremendous health care costs. 
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CHAPTER II 
EFEFCTS OF ORAL ADMINISTRATION OF L-ARGININE ON 
STREPTOZOTOCIN INDUCED DIABETIC RATS 
 
Synopsis 
L-arginine is the substrate for synthesis of nitric oxide (NO), the endothelium-
derived relaxing factor essential for regulating vascular tone and hemodynamics. In 
recent years, there has been growing interest in the use of L-arginine to prevent and treat 
the impaired endothelium-dependent relaxation associated with major cardiovascular 
risk factors (e.g. diabetes). However, little is known about the mechanism responsible 
for the stimulatory effect of arginine on endothelial NO synthesis in diabetic  and normal 
subjects. In the present study, the effect of dietary arginine supplementation on body 
weight changes, EC BH4 availability, EC NO synthesis, and plasma glucose 
concentrations in male Sprague-Dawley (SD) rats was studied. Diabetes in SD rats was 
induced by intravenous injection of streptozotocin (STZ). STZ-diabetic SD rats were 
individually pair-fed a casein-based diet on the basis of feed intake (per kg body weight) 
by non-diabetic rats. Addition of arginine-HCl (1.51%) or alanine (2.55%) to drinking 
water for the rats were adjusted daily to ensure isonitrogenous provision per kg body 
weight. In non-diabetic rats, arginine supplementation had no effect on feed intake, body 
weight or plasma glucose, but increased plasma concentrations of arginine (144%), 
plasma concentrations of insulin (44%), and arginine concentrations (88%), BH4 
concentrations (106%) and NO synthesis (80%) in EC, compared with alanine treatment. 
In diabetic rats, arginine supplementation reduced body weight loss (36%), and plasma 
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glucose levels (54%), and increased plasma arginine levels (110%), plasma insulin levels 
(209%), and arginine concentrations (173%), BH4 concentrations (128%), and NO 
synthesis (125%) in EC, compared with alanine treatment.  Results of this study 
demonstrate that dietary L-arginine supplementation is beneficial for preventing 
hyperglycemia and enhancing endothelial BH4 availability for NO synthesis in diabetic 
rats. 
 
Introduction 
A goal of the treatment of diabetes mellitus is to control plasma glucose 
concentrations. Hyperglycemia, the hallmark of diabetes mellitus, may initiate 
endothelial dysfunction, which results from decreased production of NO, inactivation of 
NO by oxygen-derived free radicals, and/or increased production of endothelium-
derived cont racting factors (opposing the protective activity of NO) (3). L-Arginine is 
the substrate for the NOS, which is responsible for the endothelial production of NO 
(20). Thus, utilization of L-arginine and its conversion to NO may contribute to a 
beneficial role of this amino acid in ameliorating endothelial dysfunction. 
L-Arginine supplementation may be beneficial for diabetic subjects. For 
example, Mendez and Balderas (32) reported that L-arginine supplementation reduced 
serum glucose and lipid levels in diabetic rats. Interestingly, administration of L-arginine 
reversed endothelial dysfunction, restored the NO-mediated endothelium-dependent 
relaxation, and decreased oxidative stress in diabetic rats (41,43). In diabetes, NO 
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synthesis is reduced in the wound milieu and hence, arginine improves wound healing 
(an angiogenesis-dependent process), by restoring NO synthesis (51).  
Despite the foregoing, little is known about the mechanisms responsible for the 
stimulating effect of arginine on endothelial NO synthesis in normal and diabetic 
subjects. Wu and Meininger (60) reported that impaired NO synthesis in EC of diabetic 
BB rats was not due to alterations in arginine uptake, NOS activity, or intracellular 
arginine concentrations but  might have resulted from a limited availability of cofactors of 
NOS. Recently, Meininger et al. (13) found that EC from the spontaneously diabetic BB 
rat have an impaired ability to produce NO due to a deficiency of BH4 and replenishing 
BH4 levels in the EC restores their ability to make NO. On the basis of the recent report 
(61) that arginine stimulates BH4 synthesis in cultured EC, we hypothesized that dietary 
L-arginine supplementation may increase BH4 availability for NO synthesis in EC of 
diabetic rats. The major objective of the present study was to test this hypothesis with 
use of STZ-induced diabetic rats.  
 
Materials and Methods  
Chemicals. Hexokinase, glucose-6-phosphate dehydrogenase and nitrate 
reductase were purchased  from Roche (Indianapolis, IN). Joklik's modified minimal 
essential medium, Dulbecco's phosphate-buffered saline, Dulbecco's modified Eagle's 
medium (DMEM), L-glutamine and penicillin/streptomycin/amphotericin B were 
obtained from GIBCO-BRL (Gaithersburg, MD). Collagenase type-II was purchased 
from Worthington Biochemical (Freehold, NJ). Heparin sodium was purchased from 
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Elkins-Sinn (Cherry Hill, NJ), whereas 2,3-daminonaphthalene (DAN), dithioerythritol, 
and streptozotocin were from Sigma (St. Louis, MO).  
Animals. Male Sprague-Dawley (SD) rats (65 days-old) were obtained from 
Harland (Houston, TX). At 70 days of age, SD rats received i.v. injection of 
streptozotocin (STZ; 65 mg/kg body wt) to induce diabetes or of vehicle solution (50 
mM sodium citrate, pH 4.5).  One day after the injection, rats received drinking water 
containing either 0.6% L-arginine-HCl (equivalent to 0.5% arginine) or 1.01% L-alanine 
(isonitrogenous control) (n = 8 per treatment, a 2 X 2 factorial design). This dose is 
chosen because it has shown to prevent endothelial dysfunction in BB rats and STZ-
diabetic rats and had no adverse effect on non-diabetic rats. The free arginine base was 
not used because 0.6% in water yields an alkaline solution (pH 10.2), while 0.6% 
arginine-HCl in water did not affect pH (5.8).  Addition of arginine or alanine to 
drinking water for rats was adjusted daily to ensure isonitrogenous provision of nitrogen 
per kg body weight. Diabetic rats were individually pair- fed a casein-based diet on the 
basis of feed intake by non-diabetic rats (per kg body wt). Table 2.1 shows the 
composition of the casein-based diet (62). Tail venous blood samples (0.2 ml) were 
obtained from SD rats on day 2 post arginine supplementation. Following two-week 
arginine supplementation to SD rats, blood samples (tail vein and heart) and coronary 
EC were obtained as described below. 
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TABLE 2.1 
Diet composition for SD rats (casein–based diet) 
 
Ingredient  20% Casein Diet   
  (g/kg diet) 
 
 
Casein1   200   
DL-Methionine  3     
Corn starch  150       
Sucrose  500            
Cellulose  50    
Corn oil  50      
Salt mix2   35    
Vitamin mix3   10     
Choline bitartrate  2    
TOTAL  1000        
Gross Energy (kJ/kg)  16,816 
   
 
 1Acid casein (88.1% protein) (New Zealand Milk Products, Inc., Santa Rosa, 
CA).  Amino acid composition of acid casein was as follows (g amino acid/100 g 
protein): alanine, 2.6; arginine, 3.6; aspartate plus asparagine, 6.5; cysteine plus cystine, 
0.4; glutamate plus glutamine, 20.9; glycine, 1.8; histidine, 2.6; isoleucine, 4.8; leucine, 
8.8; lysine, 7.4; methionine, 2.6; phenylalanine, 5.0; proline, 11.7; serine, 5.4; threonine, 
3.8; tryptophan, 1.2; tyrosine, 5.3; and valine, 5.7.   
 2Containing the following (g/kg salt mix): calcium phosphate dibasic (29.5% Ca 
and 22.8% P), 500; magnesium oxide (60.3% Mg), 24; manganous carbonate (47.8% 
Mn), 3.5; potassium citrate.1 H2O (36.2% K), 220; potassium sulfate (44.9% K and 
18.4% S), 52; sodium chloride (39.3% Na and 60.7% Cl), 74; chromium potassium 
sulfate.12 H2O (10.4% Cr), 0.55; cupric carbonate (57.5% Cu), 0.3; potassium iodate 
(59.3% I), 0.01; ferric citrate (21.2% Fe), 6.0; sodium selenite (45.7% Se), 0.01; zinc 
carbonate (52.1% Zn), 1.6; sucrose, 118.03.  
 3Containing the following (g/kg vitamin mix): retinyl palmitate (500,000 IU/g), 
0.8; cholecalciferol (100,000 IU/g), 1.0; all- rac-?-tocopheryl acetate (500 IU/g), 10.0; 
menadione sodium bisulfite (62.5% menadione), 0.08; biotin (1.0%), 2.0; 
cyanocobalamin (0.1%), 1.0; folic acid, 0.2; nicotinic acid, 3.0; calcium pantothenate, 
1.6; pyridoxine.HCl, 0.7; riboflavin, 0.6; thiamin.HCl, 0.6; sucrose, 978.42. 
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Isolation of coronary EC. Rats were injected with heparin sodium (130 U/100 g 
body wt) intraperitoneally, 20 min before the rats were euthanized. Rats were 
anesthetized by intraperitoneal injection of pentobarbital sodium (35mg/250g rat). The 
hearts were removed and placed in ice-cold Joklik's  modified minimal essential medium 
containing 60 mM taurine, 20 mM creatine, and 5 mM HEPES. The aortas were 
cannulated with stainless steel tubing (2-mm inner diameter) and perfused with the above  
medium from a static 40-mmHg hydrostatic pressure head. The oxygenated (100%) 
perfusate, which was supplemented with 0.1% dialyzed bovine  serum albumin and 
heparin (1 U/ml), was passed through the hearts once. After a 10-min washout period, 
new medium with collagenase (0.7 mg/ml) was introduced, and the perfusate was 
allowed to recirculate  until the aortic perfusion pressure decreased to below 40 mmHg 
(30-40 min). The ventricles were cut from the hearts, minced, and placed in fresh 
collagenase-containing perfusate. The tissue  was shaken at 250 rpm in a water bath for 
10 min. CaCl2 (50 µM) was added to the minced tissue, and digestion with collagenase  
continued for an additional 10 min. The cells were dispersed, filtered through a double 
layer of cheesecloth, and diluted 1:4  with buffer containing 0.1% dialyzed bovine serum 
albumin. The resulting suspension was allowed to settle to separate myocytes (which are 
heavier) from EC. EC were further purified by centrifugation through cushions of 6% 
and 3% bovine serum albumin in Joklik's modified minimal essential medium. The 
endothelial identity of the collected cells was confirmed by the uptake of modified low-
density lipoprotein.  
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Measurement of plasma glucose, arginine, and insulin. Plasma glucose 
concentration was determined by an enzymatic method involving hexokinase and 
glucose-6-phosphate dehydrogenase (63). Arginine levels in plasma were measured by 
HPLC (60). Insulin was analyzed using a radioimmunological assay kit from Linco 
Company (St. Louis, MO).  
High-performance liquid chromatography analysis of BH4 and arginine in 
freshly isolated EC. Cellular content of BH4 was determined using a modification of the 
HPLC method of Fukushima and Nixon (64). EC were lysed in 0.3 ml of 0.1 M 
phosphoric acid containing 5mM dithioerythritol (an antioxidant) and 35ul of 2M 
trichloroacetic acid. Cell debris was removed by centrifugation. Extracts were oxidized 
with acidic or basic iodine. Acidic iodine oxidation quantitatively converts BH4 and 
dihydrobiopterin to biopterin; basic iodine oxidation converts dihydrobiopterin to 
biopterin. Samples were incubated in the dark for 1 hr. Excess iodine was removed by 
adding ascorbic acid (final concentration 0.1M). The final solution was analyzed on a 
C18 reversed-phase column using fluorescence detection and authentic biopterin as a 
standard. The amount of BH4 in the extracts was determined from the difference in 
biopterin concentrations generated with acidic and basic iodine oxidation. Arginine 
levels in EC were measured by HPLC (60). Intracellular concentrations of BH4 and 
arginine were calculated on the basis of the average cell volume of rat coronary EC 
(0.348 µL/106 cells). 
NO synthesis in freshly isolated EC. EC were rinsed with the Basal Medium 
Eagle, and then incubated at 37°C for 6 hours in the Basal Medium Eagle containing 0.2 
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mM L-arginine, 0.5 mM L-glutamine, 5 mM D-glucose, 100 units/ml penicillin, 
100 µg/ml streptomycin and 0.25 µg/ml amphotericin B. At the end of the 6-h 
incubation period, media were analyzed for nitrite and nitrate (two major stable end 
products of NO oxidation) with HPLC as described by Li et al (65). In all experiments, 
medium incubated without cells were run as the blank.  
Data analysis. Results are expressed as mean ± SEM. Data were statistically 
analyzed by two-way analysis of variance using SAS (Statistical Analysis System). 
Differences between means were determined by the Student-Newman-Keul’s multiple 
comparison test.  Probability values less than 0.05 were taken to indicate significance. 
 
Results 
Body weight. Body weights of rats were recorded daily from the beginning of 
the experiment. Table 2.2 summarizes data on initial and final body weights as well as 
body weight changes. At the conclusion of the study (14 days after the onset of 
diabetes), in diabetic rats, treatment with L-arginine reduced (P< 0.01) the body weight 
loss by ~36% compared with alanine-treated rats. However, in non-diabetic rats, L-
arginine supplementation had no effect (P > 0.05) on body weight compared with the 
corresponding alanine-treated rats. There was a significant decrease (P<0.01) in the body 
weight of the alanine-treated diabetic rats due to uncontrolled diabetes.  
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TABLE 2.2 
Body weights of SD rats (g) 
 
Animals   Treatment Initial body Final body Change in body
  weight (d 0)   weight (d 14) weight gain 
 
 
Non-diabetic      Alanine  284 ± 9.0 319 ± 12  34 ± 2.7   
 Arginine 287 ± 4.9  319 ± 5.7    32 ± 1.5  
 
Diabetic  Alanine 283 ± 4.0   167 ± 3.6 * -116 ± 3.3 * 
 Arginine 282 ± 8.2 208 ± 10 *† -74 ± 8.1 *† 
 
 
Data are means ± SEM, n = 8.   
* P < 0.01 vs the corresponding non-diabetic group. 
† P < 0.01 vs the corresponding alanine-supplemented group. 
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TABLE 2.3 
Feed, water and calorie intake (g/kg body wt/day) by SD rats 
  
Animals   Treatment  Feed     Water      Gross Calorie † 
         (g/kg body wt/d)      (ml/kg body wt/d)    (kJ/kg body wt/d) 
 
 
Non-diabetic   Alanine   56.3 ± 2.2  110 ± 9.1 1008 ± 36 
 Arginine  53.2 ± 2.0   101 ± 10.4 933 ± 34 
  
Diabetic  Alanine  53.5 ± 2.3    420 ± 16.3 958 ± 35 
 Arginine  54.8 ± 2.4  341 ± 19.3 958 ± 39 
 
 
Data are means ± SEM, n = 8.   
† Including diet and drinking water. 
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Energy, food and water intake. Food and water consumption were measured 
every 24 hours. Table 2.3 summarizes the data on feed intake and water intake of rats. 
Food intake was similar among the four groups of rats to make their diets 
isonitrogenuos. Arginine and alanine intake from drinking water (Table 2.4) were 
adjusted daily to ensure isonitrogenous provision per kg body weight. Table 2.5 
summarizes the data on arginine and alanine intake from diet. Energy intake (Table 2.3) 
was calculated from the feed intake and water consumption for all four groups of rats. 
 
 
 
TABLE 2.4 
Intake of arginine from drinking water (g/kg body wt/d) by SD rats 
 
Animals    Treatment Arginine from    Alanine from  
  drinking water    drinking water 
 
 
Non-diabetic     Alanine ----      3.44 ± 0.23  
 Arginine 1.40 ± 0.12   ----      
 
Diabetic  Alanine ----        3.23 ± 0.26 
 Arginine 1.33 ± 0.12 ----           
 
 
Data are means ± SEM, n = 8.   
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TABLE 2.5 
Intake of arginine from diet (g/kg body wt/d) by SD rats 
 
Animals   Treatment Arginine from Alanine from  
  diet diet 
 
 
Non-diabetic         Alanine  0.36 ± 0.014          0.25 ± 0.006 
 Arginine 0.34 ± 0.013         0.24 ± 0.002 
 
Diabetic  Alanine 0.34 ± 0.015         0.26 ± 0.005
 Arginine 0.35 ± 0.015         0.25 ± 0.004 
 
 
Data are means ± SEM, n = 8.   
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Plasma glucose levels. All rats receiving STZ-injection developed diabetes 
within 24 h of administration on the basis of glucosuria, ketosis, and hyperglycemia and 
body weight loss, likely due to lot of fluid loss. Plasma glucose levels were higher in 
both L-arginine-treated and alanine-treated diabetic rats compared with non-diabetic rats 
at day 2 post onset of diabetes (Table 2.6). At day 14 post onset of diabetes, plasma 
glucose levels were reduced (P<0.01) in arginine-treated rats to values similar to those 
for non-diabetic rats (Table 2.6). 
 
 
TABLE 2.6 
Plasma concentrations of glucose in SD rats after arginine supplementation 
 
Animals   Treatment  Glucose (mM) 
  ________________________________________
              day 2     day 14 
 
Non-diabetic        Alanine 8.38 ± 0.8   7.73 ± 0.61  
Arginine 7.91 ± 4.1   7.66 ± 0.68 
 
Diabetic  Alanine 19.8 ± 1.7   17.8 ± 2.10 * 
 Arginine 16.9 ± 1.9   8.15 ± 0.99 † 
 
 
Data are means ± SEM, n = 8.   
* P < 0.01 vs the corresponding non-diabetic group. 
† P < 0.01 vs the corresponding alanine-supplemented group. 
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TABLE 2.7 
Plasma concentrations of arginine and insulin in SD rats after 14-day arginine 
supplementation 
 
Animals   Treatment Arginine   Insulin   
  (uM)   (ng/ml) 
  
 
Non-diabetic        Alanine 203 ± 7.8   3.42 ± 0.11  
 Arginine 496 ± 18 †   4.86 ± 0.31 †  
 
Diabetic  Alanine 137 ± 5.6 *   0.42 ± 0.04 *  
 Arginine 289 ± 14 *†   1.30 ± 0.15 *† 
  
 
Data are means ± SEM, n = 8.   
* P < 0.01 vs the corresponding non-diabetic group. 
† P < 0.01 vs the corresponding alanine-supplemented group. 
 
 
 
   
 
31 
 
 
 
 
Plasma insulin and arginine levels. Untreated diabetic rats exhibit low levels of 
plasma insulin and arginine (P<0.01), which were restored with arginine 
supplementation (Table 2.7). In diabetic rats, arginine treatment increased (P<0.01) 
plasma insulin levels by ~209% and plasma arginine levels by ~110% compared with 
alanine-treated diabetic rats. Additionally, arginine supplementation increased (P<0.01) 
plasma insulin (~44%) and arginine (~ 144%) levels in non-diabetic rats. 
Intracellular concentrations of arginine, BH4, and NO production in rat 
coronary EC. BH4 levels, arginine levels and NO production were decreased (P<0.01) 
in EC from diabetic animals, compared with non-diabetic rats (Table 2.8). However, 
arginine treatment for 14 days increased (P<0.01) arginine concentrations, BH4 
concentrations and NO production in coronary EC of both diabetic and non-diabetic rats. 
In diabetic rats, arginine treatment increased (P<0.01) arginine concentrations, BH4 
concentrations and NO production in coronary EC by ~ 173%, 128%, 125%, 
respectively, compared with the corresponding alanine-treated rats. In non-diabetic rats, 
arginine supplementation increased (P<0.01) arginine concentrations, BH4 
concentrations and NO production in coronary EC by 88%, 106%, and 80%, 
respectively, compared with the corresponding alanine-treated rats.  
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TABLE 2.8 
Intracellular concentrations of arginine, BH4 and NO production in SD rat coronary 
endothelial cells after 14-day arginine supplementation 
  
Animals  Treatment [Arginine] [BH4]    NO synthesis 
   (mM)  (uM)       (pmol/106 cells per h) 
 
 
Non-diabetic   Alanine  1.29 ± 0.06 2.94 ± 0.20  259 ± 12
 Arginine 2.43 ± 0.10 † 6.03 ± 0.03 † 468 ± 19 † 
 
Diabetic  Alanine 0.49 ± 0.03 * 1.40 ± 0.06 * 118 ± 8.1 * 
 Arginine 1.34 ± 0.08 *† 3.22 ± 0.03 *† 266 ± 18 † 
 
 
Data are means ± SEM, n = 8.   
* P < 0.01 vs the corresponding non-diabetic group. 
† P < 0.01 vs the corresponding alanine-supplemented group. 
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Discussion 
Endothelial dysfunction is a major factor contributing to morbidity and mortality 
in diabetes mellitus. Enhanced production of vasoconstrictors and/or reduced synthesis 
of the vasodilator, NO may be the most important factors responsible for diabetes-
associated cardiovascular complications (13). A deficiency of arginine or BH4 could 
impair the endothelium-dependent relaxation. As reported by other investigators (11.12), 
we observed a marked decrease in plasma concentrations of arginine in diabetic rats. 
This provides a basis for dietary supplementation of arginine as a potentially novel 
means to prevent diabetes-associated endothelial dysfunction.  
Our results demonstrate that oral administration of L-arginine-HCl via drinking 
water for 14 days decreased (P<0.01) glucose levels in diabetic rats by ~54%. This is a 
very significant finding, but the mechanism is not known at present. Arginine 
supplementation may stimulate NO production by skeletal muscle, and enhance NO-
mediated blood flow, thereby increasing glucose uptake by skeletal muscle and insulin 
sensitivity in tissues. Beneficial effects of L-arginine administration on serum glucose 
levels have also been demonstrated in other studies (32). Indeed, Popov et al (66) 
reported that oral administration of 622 mg arginine/kg body weight to hamsters reduced 
the high concentrations of circulating glucose by 63%. L-Arginine is known to stimulate 
the secretion of insulin from beta cells of the pancreas (23,36). Indeed, dietary 
supplementation of L-arginine resulted in an increase in the plasma insulin levels in both 
STZ-induced diabetic (by ~209%) and non-diabetic (by ~44%) SD rats. Note that in the 
STZ-diabetic rat model, not all the ß-cells are destroyed, and the remaining cells can 
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secret a physiologically significant quantity of sufficient insulin to keep the animals 
alive for up to 2 months.  
An important finding of this study is that L-arginine supplementation ameliorated 
weight loss in STZ diabetic rats. SD diabetic rats treated with L-arginine had 36% less 
weight loss than alanine-treated diabetic rats. The ability of L-arginine to reduce body 
weight loss in STZ-diabetic rats may result from one or more of the following factors: 1) 
prevention of hyperglycemia, 2) reduction in skeletal muscle protein degradation, and 3) 
increase in skeletal muscle protein synthesis. L-Arginine supplementation did not affect 
the weight gain, plasma glucose levels, food and water intake in normal, non-diabetic 
rats, indicating a lack of adverse effect of elevated levels of arginine under the 
experimental conditions of the study. 
Previous work (67) in our lab showed that rates of arginine degradation by 
enterocytes of the small intestine did not differ between normal and STZ-diabetic rats. 
Thus, similar amounts of dietary arginine would be expected to enter the portal 
circulation in normal and STZ-diabetic rats. L- Arginine treatment increased arginine 
levels by almost two folds (~110%) compared with alanine-treated diabetic rats. The 
reasons for decreased plasma arginine in diabetic state are unclear. However, previous 
work in our lab suggests that the reduced availability of circulating arginine in diabetic 
rats may result from impaired renal arginine synthesis owing to reduced availability of 
aspartate (an amino acid required for the conversion of citrulline into arginine by 
argininosuccinate synthase). Nevertheless, results of this study indicate that oral 
administration is an effective means to augment plasma arginine levels in diabetic rats.  
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Intracellular arginine concentrations are approximately 1-2 mM in freshly 
isolated endothelial cells. Intracellular values of L-arginine (0.49 mM) in diabetic SD 
rats were substantially decreased but were still much higher than the Km value of eNOS 
(2.9 mM) for L-arginine. This observation implies that endothelial NOS was saturated 
with intracellular L-arginine. However, dietary supplementation of L-arginine did 
increase NO production in coronary EC of both STZ-diabetic and non-diabetic SD rats 
(Table 2.8). This data further supports the notion that intracellular or extracellular 
arginine concentrations are critical for endothelial NO production. Importantly, we 
found that L-arginine increased endothelial BH4 availability in both STZ-diabetic and 
non-diabetic SD rats. This finding is consistent with the report that replenishing BH4 
levels in EC from diabetic animals restores their ability to make NO (13). Through an 
increase in BH4 availability, administration of L-arginine increased endothelial NO 
generation.  
 In conclusion, dietary arginine supplementation to STZ-diabetic rats increased 
plasma and EC concentrations of arginine, and enhanced BH4 availability and NO 
synthesis in EC. In addition, the arginine treatment prevented hyperglycemia and 
reduced the loss of body weight in diabetic animals. These data demonstrate that oral 
administration of arginine is beneficial for an animal model of insulin-dependent 
diabetes mellitus. The findings also provide a biochemical basis for explaining the 
beneficial effect of dietary arginine supplementation to diabetic human patients. 
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CHAPTER III 
EFEFCTS OF ORAL ADMINISTRATION OF L-ARGININE ON ZUCKER 
DIABETIC FATTY RATS 
 
Synopsis 
This study was conducted to test the hypothesis that dietary arginine 
supplementation would increase the availability of tetrahydrobiopterin (BH4) for NO 
synthesis in endothelial cells (EC) of type-II diabetic rats, thereby preventing endothelial 
dysfunction. Male Zucker diabetic fatty (ZDF) rats were individually pair-fed a Purina 
5008 diet on the basis of feed intake by alanine-treated diabetic rats (per kg body wt). 
Addition of arginine-HCL (1.51%) or alanine (2.55%) to drinking water for ZDF rats 
was adjusted daily to ensure isonitrogenous provision per kg body weight. Plasma 
glucose levels were determined in tail venous  blood samples, obtained at weeks 3, 6 and 
10 post arginine supplementation. At the end of a 10-week period of arginine 
supplementation, blood samples and coronary EC were obtained from rats. Arginine 
supplementation did not affect (P>0.05) plasma levels of glucose and insulin, compared 
with alanine-treated rats, but reduced (P<0.01) epididydmal fat (30%), abdominal fat 
(43%) and body weight gain and increased (P<0.01) plasma concentrations of arginine 
(273%), and arginine concentrations (197%), BH4 concentrations (120%) and NO 
synthesis (122%) in EC, compared with alanine-treated rats. These results indicate that 
oral administration of arginine enhances BH4 availability for NO synthesis in EC of ZDF 
rats and that arginine is a novel anti-obesity nutrient. Collectively, dietary arginine 
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supplementation may be beneficial for obese subjects with insulin- independent diabetes 
mellitus.  
 
Introduction 
Type-II diabetes mellitus and obesity commonly co-occur. Weight loss in obese-
diabetic patients is associated with significant health benefits, including improved 
glycemic control and reduced blood pressure (68). NO, synthesized from L-arginine by 
eNOS, has emerged as an important therapeutic molecule for enhancing insulin 
sensitivity and preventing endothelial dysfunction in diabetic subjects (25). Nisoli et al 
(30) reported that NO plays a major role in mitochondrial biogenesis in a cGMP-
dependent manner. Interestingly, NOS null-mutant mice had a reduced metabolic rate 
and accelerated weight gain (30), insulin resistance (27), hypertension, and 
hyperlipidemia (31). Other studies have also shown the evidence of NO role in 
regulation of lipolysis (69) by facilitating leptin- induced lipolysis (70). These findings 
suggest a possible role of NO as an anti-obesity agent. 
Recent data from our laboratory indicate that BH4 is deficient in EC of both STZ-
diabetic rats and ZDF rats. Results presented in chapter II of this thesis demonstrate that 
dietary arginine supplementation to STZ-diabetic rats increased BH4 concentrations and 
NO production in coronary EC. In view of this finding, we hypothesized that dietary 
arginine supplementation could also increase the availability of BH4 for NO synthesis in 
EC of ZDF rats, thereby preventing endothelial dysfunction.  
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Materials and Methods 
Chemicals. Hexokinase, glucose-6-phosphate dehydrogenase and nitrate 
reductase were purchased  from Roche (Indianapolis, IN). Joklik's modified minimal 
essential medium, Dulbecco's phosphate-buffered saline, Dulbecco's modified Eagle's 
medium (DMEM), L-glutamine and penicillin/streptomycin/amphotericin B were 
obtained from GIBCO-BRL (Gaithersburg, MD). Collagenase type-II was purchased 
from Worthington Biochemical (Freehold, NJ). Heparin sodium was purchased from 
Elkins-Sinn (Cherry Hill, NJ), whereas 2,3-diaminonaphthalene (DAN), dithioerythritol, 
and streptozotocin were from Sigma (St. Louis, MO).  
  Animals. Male Zucker diabetic fatty rats (ZDF) (8 week-old) were obtained from 
Charles River (Wilmington, MA). At 9 weeks of age, ZDF rats received drinking water 
containing either 1.51% L-arginine-HCl or 2.55% L-alanine (isonitrogenous control) (n 
= 5 per treatment). This dose is chosen because previous studies have shown that oral 
administration of arginine (1.2% in drinking water) prevented endothelial dysfunction in 
BB rats and STZ-diabetic rats and had no adverse effect on non-diabetic rats (41). The 
free arginine base was not used because 1.2% or 1.51 % in water yields an alkaline 
solution (pH 10.8), while 1.5% arginine-HCl in water did not affect pH (6.5). Addition 
of arginine or alanine to drinking water for diabetic rats was adjusted daily to ensure 
isonitrogenous provision of nitrogen per kg body weight. Diabetic rats were individually 
pair- fed a Purina 5008 diet on the basis of feed intake by alanine-treated diabetic rats 
(per kg body wt). The ingredients of the Purina 5008 diet are shown in Table 3.1 and 
composition of the diet in Table 3.2. Tail venous blood samples (0.2 ml) were obtained 
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from ZDF rats at weeks 3, 6 and 10 post arginine supplementation. At the end of a 10-
week period of arginine supplementation, blood samples and coronary EC were obtained 
from ZDF rats as described below.  
 
 
TABLE 3.1 
Ingredients of Purina 5008 diet for ZDF rats 
 
 
Ground corn  Dehulled soybean meal   Ground wheat 
Fish meal  Wheat middlings    Animal fat  
Cane molasses  Ground oats    Brewers dried yeast  
Wheat germ meal  Meat meal    Dried beet pulp  
Dehydrated alfalfa  Calcium carbonate   Dried whey  
Salt  Cyanocobalamin    DL-methionine  
Calcium   Pantothenate    Choline chloride  
Folic acid,  Pyridoxine hydrochloride  Riboflavin  
Thiamin mononitrate  Nicotinic acid    Vitamin A acetate  
Cholecalciferol  DL-alpha tocopheryl acetate  Manganous oxide  
Ferrous carbonate  Cobalt carbonate    Calcium iodate  
Copper sulphate  Zinc sulphate    Zinc oxide  
Vitamin K † 
 
 
† Provided as Menadione dimethylpyrimidinol bisulfite.
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TABLE 3.2 
 
Nutrient composition of Purina 5008 diet for ZDF rats 
  
Nutrients  
       
Protein        23.5 % 
Arginine      1.44 % 
 Cystine      0.35 % 
 Glycine      1.23 % 
 Histidine      0.58 % 
 Isoleucine      1.20 % 
 Leucine         1.87 % 
 Lysine       1.40 % 
 Methionine      0.43 % 
 Phenylalanine      1.08 % 
 Tyrosine      0.66 % 
 Threonine      0.90 % 
Tryptophan                             0.28 % 
 Valine       1.19 % 
 Serine        1.20 % 
 Aspartic Acid       2.60 % 
            Glutamic Acid   4.77 % 
 Alanine      1.39 % 
 Proline        1.63 % 
 Taurine      0.02 % 
Fat (ether extract)      6.5 % 
Fat (acid hydrolysis)      7.5 % 
Cholesterol, ppm     280  
Linoleic acid       1.37 % 
Linolenic acid       0.09 % 
Arachidonic acid     0.01 % 
Omega-3 fatty acids     0.29 % 
Total Saturated fatty acids    2.51 % 
 Total Monounsaturated fatty acids   2.32 % 
Fiber 3.8 % 
Nitrogen-free extract      49.4 % 
 Starch       34.9 % 
 Glucose      0.22 % 
Fructose      0.24 % 
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TABLE 3.2  Continued 
 
Nutrients        
 
 Sucrose      2.57 %  
 Lactose     0.39 % 
Total digestible Nutrients     81.2 %   
Minerals  
Ash       6.8 %  
 Calcium 1.0 %  
 Phosphorus   0.65 % 
 Potassium      1.10 % 
 Magnesium      0.20 % 
 Sulfur       0.24 % 
 Sodium 0.28 % 
 Chlorine 0.48 % 
 Fluorine, ppm 19  
 Iron, ppm 230  
 Zinc, ppm 73  
 Manganese, ppm 71  
 Copper, ppm  13  
 Cobalt, ppm 0.4  
 Iodine, ppm  0.8  
 Chromium, ppm     1.4  
 Selenium, ppm     0.23 
Vitamins 
 Carotene, ppm      4.0    
 Vitamin K (as menadione), ppm   3.2 
 Thiamine Hydrochloride, ppm   16 
 Riboflavin, ppm     5.0 
 Niacin, ppm      109 
 Pantothenic Acid, ppm    15 
 Choline Chloride, ppm    2000 
 Folic Acid, ppm     3.0 
 Pyridoxine, ppm     6.0 
 Biotin, ppm      0.20   
 B12, mcg/kg      20 
 Vitamin A, IU/gm 15 
 Vitamin D3 (added), IU/gm  3.3 
Vitamin E, IU/kg 55 
Ascorbic Acid, mg/gm --- 
Gross Energy, kJ/kg      17364 
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Isolation of coronary EC. Rats were injected with heparin sodium (130 U/100 g 
body wt) intraperitoneally, 20 min before the rats were euthanized. Rats were 
anesthetized by intraperitoneal injection of pentobarbital sodium (35mg/250g rat). The 
hearts were removed and placed in ice-cold Joklik's  modified minimal essential medium 
containing 60 mM taurine, 20 mM creatine, and 5 mM HEPES. The aortas were 
cannulated with stainless steel tubing (2-mm inner diameter) and perfused with the above  
medium from a static 40-mmHg hydrostatic pressure head. The oxygenated (100%) 
perfusate, which was supplemented with 0.1% dialyzed bovine  serum albumin and 
heparin (1 U/ml), was passed through the hearts once. After a 10-min washout period, 
new medium with collagenase (0.7 mg/ml) was introduced, and the perfusate was 
allowed to recirculate  until the aortic perfusion pressure decreased to below 40 mmHg 
(30-40 min). The ventricles were cut from the hearts, minced, and placed in fresh 
collagenase-containing perfusate. The tissue  was shaken at 250 rpm in a water bath for 
10 min. CaCl2 (50 µM) was added to the minced tissue, and digestion with collagenase  
continued for an additional 10 min. The cells were dispersed, filtered through a double 
layer of cheesecloth, and diluted 1:4  with buffer containing 0.1% dialyzed bovine serum 
albumin. The resulting suspension was allowed to settle to separate myocytes (which are 
heavier) from EC. EC were further purified by centrifugation through cushions of 6% 
and 3% bovine serum albumin in Joklik's modified minimal essential medium. The 
endothelial identity of the collected cells was confirmed by the uptake of modified low-
density lipoprotein.  
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Measurement of plasma glucose, arginine, and insulin. Plasma glucose 
concentration was determined by an enzymatic method involving hexokinase and 
glucose-6-phosphate dehydrogenase (63). Arginine levels in plasma were measured by 
HPLC (60). Insulin was analyzed using a radioimmunological assay kit from Linco 
Company (St. Louis, MO). 
High-performance liquid chromatography analysis of BH4 and arginine in 
freshly isolated EC. Cellular content of BH4 was determined using a modification of the 
HPLC method of Fukushima and Nixon (64). EC were lysed in 0.3 ml of 0.1 M 
phosphoric acid containing 5mM dithioerythritol (an antioxidant) and 35ul of 2M 
trichloroacetic acid. Cell debris was removed by centrifugation. Extracts were oxidized 
with acidic or basic iodine. Acidic iodine oxidation quantitatively converts BH4 and 
dihydrobiopterin to biopterin; basic iodine oxidation converts dihydrobiopterin to 
biopterin. Samples were incubated in the dark fo r 1 hr. Excess iodine was removed by 
adding ascorbic acid (final concentration 0.1M). The final solution was analyzed on a 
C18 reversed-phase column using fluorescence detection and authentic biopterin as a 
standard. The amount of BH4 in the extracts was determined from the difference in 
biopterin concentrations generated with acidic and basic iodine oxidation. Arginine 
levels in EC were measured by HPLC (60). Intracellular concentrations of BH4 and 
arginine were calculated on the basis of the average cell volume of rat coronary EC 
(0.348 µL/106 cells). 
NO synthesis in freshly isolated EC. EC were rinsed with the Basal Medium 
Eagle, and then incubated at 37°C for 6 hours in Basal Medium Eagle containing 0.2 
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mM L-arginine, 0.5 mM L-glutamine, 5 mM D-glucose, 100 units/ml penicillin, 
100 µg/ml streptomycin and 0.25 µg/ml amphotericin B. At the end of a 6-h incubation 
period, media were analyzed for nitrite and nitrate (two major stable end products of NO 
oxidation) by HPLC as described by Li et al (65). In all experiments, media incubated 
without cells were run as blanks.  
Data analysis. Results are expressed as mean ± SEM. Data were statistically 
analyzed by unpaired t-test or analysis of variance for repeated measurements using SAS 
(Statistical Analysis System). Probability values less than 0.05 were taken to indicate 
significance. 
 
Results 
Energy food and water intake. Food and water consumption were measured 
every 24 hours. Table 3.3 summarizes the data on feed intake and water intake of ZDF 
rats. Food intake was matched for L-arginine-treated and alanine-treated rats, to make 
their diets isonitrogenous. Arginine and alanine intake from drinking water (Table 3.4) 
were also adjusted daily to ensure isonitrogenous provision of nitrogen per kg body 
weight. Table 3.5 summarizes the data on arginine and alanine intake from diet. Energy 
intake (Table 3.3) was calculated from feed intake and water consumption for both 
groups of ZDF rats.  
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TABLE 3.3 
Feed, water and calorie intake by ZDF rats 
  
Treatment Feed     Water  Gross Calorie † 
                            (g/kg body wt/d)         (ml/kg body wt/d)                (kJ/kg body wt/d) 
 
 
Alanine 99.0 ± 1.0   423 ± 24 1908 ± 18 
   
Arginine     100.5 ± 1.9    472 ± 25 1894 ± 33 
    
 
Data are means ± SEM, n = 4 for alanine group and n = 5 for arginine group. 
† Including diet and drinking water. 
 
 
TABLE 3.4 
Intake of arginine and alanine from drinking water (g/kg body wt/day) by ZDF rats 
 
Treatment             Arginine from Alanine from                  
   drinking water  drinking water          
 
 
Alanine      ----          10.7 ± 0.59  
  
Arginine                            5.7 ± 0.28      ----      
 
 
Data are means ± SEM, n = 4 for alanine group and n = 5 for arginine group. 
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TABLE 3.5 
Intake of arginine and alanine from diet (g/kg body wt/day) by ZDF rats 
 
Treatment  Arginine from          Alanine from               
  diet                          diet  
     
Alanine                         1.43 ± 0.015                            1.38 ± 0.014   
  
Arginine                       1.44 ± 0.026                            1.39 ± 0.025   
 
 
Data are means ± SEM, n = 4 for alanine group and n = 5 for arginine group.  
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Body and tissue weights. Experiment with ZDF rats was started at 9 weeks of 
age. Rat weights were recorded daily. Figure 3.1 shows the change in body weights of 
ZDF rats receiving dietary supplementation of L-arginine or alanine for 10 weeks. A 
significant decrease in body weight gain (Table 3.6) was observed (P<0.01) in arginine-
treated ZDF rats from week 4 post dietary supplementation. Data on tissue weights of 
animals at week 10 after initiating arginine supplementation are summarized in Table 
3.7. Results indicate a marked decrease in epididymal fat (~30%, P<0.05) and abdominal 
fat (~43%, P<0.01) in arginine-supplemented rats, compared with control rats. Except 
for liver and pancreas, no significant differences were found in the weights of all other 
non-fat tissues examined (P>0.05). The ratio of tissue weight (Table 3.8) to whole body 
weight indicates a marked decrease (43%, P<0.01) in abdominal fat and a small decrease 
(P<0.05) in pancreas in arginine-supplemented rats, compared with control rats. There 
was a significant increase (P<0.05) in EDL muscle, soleus muscle, and brain weights in 
arginine-supplemented rats, compared with control rats.  However, for other non-fat 
tissues examined, the ratio of tissue weight to the whole body weight did not differ 
(P>0.05) between control and arginine treated ZDF rats.  
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TABLE 3.6 
Body weights of ZDF rats (g) 
 
Week  Alanine group   Arginine group 
 
 
0  338 ± 4.5   326 ± 8.8 
1  361 ± 5.3   337 ± 12.1 
2  375 ± 5.6   349 ± 12.8 
3  386 ± 9.3   344 ± 17.2 
4  368 ± 9.9   343 ± 15.3 * 
5  397 ± 9.0   349 ± 16.3 * 
6  447 ± 13.0   397 ± 15.6 * 
7  409 ± 15.6   352 ± 18.0 * 
8  404 ± 17.2   333 ± 16.1 * 
9  404 ± 19.9   344 ± 13.3 * 
10  411 ± 21.8   336 ± 13.0 * 
 
 
 Data are means ± SEM, n = 4 for alanine group and n = 5 for arginine group. 
 * P < 0.05 vs alanine treated ZDF rats group.
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     FIGURE 3.1 Changes in body weight of ZDF rats (Data are from Table 3.5). 
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TABLE 3.7 
Tissue weight (g) of ZDF rats after 10-week arginine supplementation 
 
Tissue       Treatment 
   ____________________________________________________ 
      Alanine   Arginine 
 
 
Epdidymal fat      9.38 ± 0.69   6.56 ± 0.57 * 
Abdominal fat 15.25 ± 1.34   8.64 ± 0.63 ** 
Liver 22.85 ± 1.30   17.75 ± 1.06 * 
Pancreas 1.69 ± 0.05    1.14 ± 0.06 ** 
EDL Muscle † 0.12 ± 0.004   0.11 ± 0.005 
Soleus Muscle 0.13 ± 0.008   0.12 ± 0.004  
Small Intestine  14.28 ± 1.1   12.68 ± 0.35 
Kidney 4.21 ± 0.08   3.95 ± 0.18 
Brain 1.72 ± 0.05   1.69 ± 0.03 
Heart 1.55 ± 0.12   1.47 ± 0.07 
Lung 1.05 ± 0.11   1.28 ± 0.05 
Spleen 0.62 ± 0.042   0.52 ± 0.032 
Testes 2.63 ± 0.13   2.49 ± 0.13 
 
 
Data are means ± SEM, n = 4 for alanine group and n = 5 for arginine group.  
† EDL = Extensor Digitorium Longus Muscle. * * P < 0.01, * P < 0.05 by t-test. 
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TABLE 3.8 
Ratio of tissue weight to whole body weight (g/kg body wt) of ZDF rats after 10-week 
arginine supplementation 
 
Tissue       Treatment 
     ____________________________________________________ 
      Alanine    Arginine 
 
 
Epdidymal fat     22.7± 0.97     19.6 ± 1.1 
Abdominal fat 36.7 ± 1.5     25.6 ± 1.2 ** 
Liver 55.4 ± 2.03    53.4 ± 2.7 
Pancreas 4.1 ± 0.17     3.4 ± 0.20 * 
EDL Muscle † 0.29 ± 0.003    0.33 ± 0.01* 
Soleus Muscle 0.31 ± 0.012    0.37 ± 0.004 *  
Small Intestine  35.2 ± 4.5    38.4 ± 1.9 
Kidney 10.2 ± 0.39    11.9 ± 0.58 
Brain 4.2 ± 0.23    5.1 ± 0.08 * 
Heart 3.7 ± 0.18    4.5 ± 0.29 
Lung 3.5 ± 0.45    4.3 ± 0.10 
Spleen 1.5 ± 0.05    1.6 ± 0.13 
Testes 6.4 ± 0.52    7.6 ± 0.58 
 
 
Data are means ± SEM, n=9. † EDL = Extensor Digitorium Longus Muscle.  
* * P < 0.01, * P < 0.05 by t-test. 
   
 
52 
 
 
 
 
Plasma glucose levels. Venous plasma was obtained from unanesthetized ZDF 
rats on weeks 3, 6 and 10 post-arginine supplementation for glucose analysis. 
Hyperglycemia (19-22 mM glucose) occurred in all ZDF rats. There was no significant 
difference (P>0.05) in plasma glucose levels (Table 3.9) between control and L-
arginine-treated rats at any sampling day. This was contrary to the results obtained with 
the STZ-diabetic rat model.  
Plasma insulin and arginine levels. At the conclusion of the study (10 week 
post-arginine supplementation), plasma arginine and insulin concentrations were 
measured. ZDF rats exhibited low levels of plasma insulin (normal physiological 
concentrations ~3-4 ng/ml) and plasma arginine (normal ~ 250-300 µM). Arginine 
supplementation increased (P<0.01) plasma arginine concentrations by ~ 274% 
compared with alanine-treated rats (Table 3.10). However, plasma insulin levels did not 
differ (P>0.05) between alanine and arginine-treated rats.  
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TABLE 3.9 
Plasma concentrations of glucose in 19-week-old ZDF rats after 10-week arginine 
supplementation 
 
 Treatment              Glucose (mM) 
           ________________________________________________________ 
       3 wk    6wk         10 wk 
 
 
Alanine  19.55 ± 0.66     22.23 ± 0.59      19.52 ± 0.42 
 
Arginine           20.41 ± 0.57       22.24 ± 0.33    18.76 ± 0.59 
  
 
Data are means SEM, n = 4 for alanine group and n = 5 for arginine group. 
 
 
 
TABLE 3.10 
Plasma concentrations of arginine and insulin in 19-week-old ZDF rats after 10-week 
arginine supplementation 
 
 Treatment   Arginine    Insulin    
         (µM)                                        (ng/ml)      
     
 
Alanine         206.9 ± 29.7          1.5 ± 0.3  
        
Arginine          773.56 ± 81.8 *   1.2 ± 0.2  
  
 
Data are means SEM, n = 4 for alanine group and n = 5 for arginine group. 
* P < 0.01 by t-test. 
   
 
54 
 
 
 
 
Intracellular concentrations of arginine, BH4, and NO production in rat 
coronary EC. BH4 levels, arginine levels and NO production were greater (P<0.01) in 
EC from arginine-treated ZDF rats compared with alanine-treated rats (Table 3.11). The 
relative increase in arginine concentration, BH4 concentration, and NO production in EC 
from ZDF rats, post arginine supplementation, was similar to those for STZ-diabetic SD 
rats.  
 
 
TABLE 3.11 
Intracellular concentrations of arginine, BH4 and NO production in coronary endothelial 
cells of 19-week-old ZDF rats after 10-week arginine supplementation 
 
Rats  [Arginine]  [BH4]   NO production 
     (mM)   (µM)            (pmol/106 cells/h) 
 
 
Alanine 0.70 ± 0.03  1.12 ± 0.06  71 ± 6 
 
Arginine 2.08 ± 0.10 *  2.47 ± 0.14 *  158 ± 9 * 
 
 
Data are means SEM, n = 4 for alanine group and n = 5 for arginine group. 
* P < 0.01 by t-test. 
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Discussion 
This is the first study to determine the effects of dietary L-arginine 
supplementation on 1) body weight, plasma concentrations of glucose, insulin and 
arginine in ZDF rats, and 2) concentrations of arginine and BH4, and NO synthesis in EC 
of ZDF rats. A novel, important finding of this work is that oral arginine administration 
to ZDF rats resulted in a significant decrease in epididymal fat (~30%) and abdominal 
fat (~43%) and in body weight. The reason for this observation is not clear at present. 
However, arginine or its product (NO) may inhibit lipogenesis and/or increase lipolysis. 
Importantly, others (30) have reported that a deficiency in the NO-cGMP-dependent 
pathway reduces mitochondrial biogenesis and promotes weight gain in mice, suggesting 
a critical role for NO in regulating body energy balance. By increasing NO synthesis, 
arginine supplementation may promote mitochondrial oxidation of fat in adipose tissue, 
liver and skeletal muscle, and thereby reducing body fat content. Except for small 
decreases in liver and pancreas weights, no significant difference was found in the 
weights of all other non-fat tissues examined. These results imply that the difference in 
body weights between control and arginine-treated ZDF rats is primarily due to changes 
in body fat. In addition, the finding suggests that adipose tissue is most sensitive to 
dietary arginine supplementation and perhaps to NO-mediated mitochondrial biogenesis. 
Future studies are necessary to determine body composition and energy expenditure in 
control and arginine-treated ZDF rats. 
In contrast to the results found with SD rats, oral supplementation of L-arginine 
did not affect plasma glucose levels in ZDF rats compared with alanine-treated animals. 
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This can be due to excess fat in the body, the oxidation of which provides energy and 
spares glucose. Oxidation of fatty acids, which results in the production of acetyl-CoA, 
inhibits glycolysis and stimulates gluconeogenesis. Importantly, gluconeogenesis also 
depends on fatty acid oxidation for ATP provision. Although plasma triglycerides levels 
were not measured in this study, it is possible, that hydrolysis of high levels of 
triglycerides may provide glycerol for hepatic gluconeogenesis. In type-II diabetic 
subjects, insulin-sensitive tissues do not efficiently utilize glucose, which may contribute 
to the elevated levels of plasma glucose (19-22 mM) in ZDF rats.  Interestingly, in 
contrast to STZ-diabetic rats, arginine did not increase plasma levels of insulin in ZDF 
rats. This finding may be due to a lack of stimulation of insulin release from pancreatic 
beta cells of ZDF rats. Plasma arginine levels were increased by arginine 
supplementation to a greater extent in ZDF rats compared with STZ-diabetic rats. This 
result may be explained by greater intake of arginine from diet and drinking water in 
ZDF rats.  
As in STZ-diabetic rats, dietary supplementation of L-arginine increased NO 
production in coronary EC of ZDF rats. Importantly, we found that L-arginine increased 
endothelial BH4 availability in ZDF rats. In both of these animal models of diabetes, the 
cellular mechanism for BH4 synthesis and the regulation of this pathway appear to be 
intact, which allows for the response of EC to elevated concentrations of extracellular 
arginine. Thus, through an increase in BH4 availability, administration of L-arginine 
restored the ability of EC to make NO in both type-I and type-II diabetes mellitus. 
Collectively, the results of this study support the hypothesis that dietary L-arginine 
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supplementation increases the availability of BH4 for NO synthesis in EC of diabetic 
rats, thereby preventing endothelial dysfunction.   
In conclusion, oral administration of arginine markedly increased endothelial 
BH4 availability and NO synthesis, and reduced abdominal and epididymal fat in ZDF 
arts. The weight–reducing effect of arginine may be mediated by NO, an activator of 
mitochondrial biogenesis. Arginine may be a novel anti-obesity nutrient, which has 
important implications for the prevention and treatment of obese, and diabetic patients. 
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CHAPTER IV 
GENERAL DISCUSSION AND CONCLUSION 
 
Arginine is Beneficial for Diabetic Rats 
L-arginine is a versatile amino acid in animal and human cells, serving as a 
precursor for the synthesis of not only proteins but also NO, creatine, agmatine, proline, 
polyamines, and other molecules involved in regulating cellular homeostatsis. L-
Arginine exerts favorable effects in humans with a number of atherosclerosis risk factors 
such as hypercholesterolemia, hypertension, smoking, and diabetes. In view of 
conflicting findings in the literature regarding the effect of arginine on endothelial 
function in diabetes (71), the present study was conducted to determine the effects of 
arginine in STZ-diabetic and ZDF rats at cellular, tissue and whole body levels. Results 
of this thesis work provide evidence for the beneficial effects of dietary intervention with 
L-arginine in both type-I and type-II diabetic subjects.  
An exciting finding of this work is that oral supplementation of L-arginine to 
STZ-induced diabetic rats prevented hyperglycemia. A daily dose of L-arginine-HCl 
(equivalent to 0.5 % arginine) in drinking water markedly decreased glucose levels in 
diabetic rats by ~54%. Hence, L-arginine possesses antihyperglycemic properties, likely 
due to an NO-mediated increase in blood flow, glucose uptake by skeletal muscle, and 
tissue insulin sensitivity. This observation is in agreement with recent data of Mendez 
and Balderas (32), who reported beneficial effects of L-arginine administration on 
reducing serum glucose levels. Further, Mohan and Das (72) demonstrated that L-
arginine and NO prevented beta-cell damage and the severe effects of diabetes. Also, 
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Popov et al. (66) reported that oral administration of 622 mg arginine/kg body weight to 
hamsters diminished the high concentrations of circulating glucose by 63%. However, 
arginine supplementation for 10 weeks is not effective in reducing plasma glucose or 
increasing plasma insulin levels in ZDF rats. This could be due to excess fat in the body, 
and hence the body uses lipid oxidation for providing energy and spares glucose. 
Oxidation of fatty acids, which result in the production of acetyl-CoA, inhibits 
glycolysis and stimulates gluconeogenesis. At the end of a 10-week period of arginine 
supplementation, there remains a substantial amount of abdominal and epididymal fat in 
ZDF rats. We expect that when a period of arginine supplementation is extended beyond 
10 weeks to deplete more body fat, arginine treatment may be able to reduce plasma 
levels of glucose. Further studies are required to test this hypothesis. 
The beneficial effect of L-arginine administration has been thought to result from 
an increase in insulin secretion by panc reatic ß-cells that are not destroyed after STZ 
injection (73). Consistent with this view, L-arginine increases the secretion of insulin 
from beta cells of the pancreas (23,36). Additionally, NO synthesis from arginine is 
known to mediate insulin release from pancreatic cells in the presence of glucose (32). 
Accordingly, arginine supplementation increased plasma insulin levels in both diabetic 
(by ~209%) and non-diabetic (by ~44%) STZ-SD animals. Interestingly, L-arginine 
supplementation had no effect on plasma insulin levels in ZDF rats, probably due to a 
lack of stimulation of insulin release from pancreatic ß-cells in this type-II diabetic 
animal model. Another possible reason may be age, as ZDF rats and STZ-diabetic rats 
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were 19 and 12 weeks old, respectively. In older animals, insulin release from ß-cells 
may not be sensitive to arginine stimulation. 
Another striking finding of this study is that L-arginine treatment reduced the 
weight loss of STZ-diabetic rats. SD diabetic rats treated with L-arginine had 36% less 
weight loss than alanine-treated diabetic rats. L-arginine supplementation did not affect 
the weight gain, food and water intake in normal, non-diabetic rats. Thus, through NO 
synthesis, arginine may improve the efficiency of utilization of dietary nutrients in type-I 
diabetic rats. It is possible that an increase in plasma insulin levels in STZ-diabetic rats 
stimulates protein synthesis and inhibits protein degradation in skeletal muscle and the 
whole body. 
The third novel, important finding of this study is that L-arginine 
supplementation promoted a significant decrease in body weight gain by ZDF rats, 
compared with alanine-treated rats. The reason for this finding is not clear at present. 
However, arginine or its product (NO) may inhibit lipogenesis and/or increase lipolysis 
(Fig. 4.1). In this regard, it is noteworthy that Nisoli et al (30) reported that the NO-
cGMP-dependent pathway controls mitochondrial biogenesis and body energy balance. 
NOS null-mutant mice had a reduced metabolic rate and accelerated weight gain. In our 
study, there were marked decreases in epididymal fat (~30%) and abdominal fat (~43%) 
in arginine-supplemented ZDF rats as compared with the alanine-treated rats. Thus, 
arginine may be a novel anti-obesity nutrient. Future studies are required to quantify 
body composition and whole body energy expenditure in control and arginine-treated 
ZDF rats 
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FIGURE 4.1 Role of arginine and NO in lipid metabolism. Abbreviations: TG, 
triglycerides; FFA, free fatty acids; GTP, guanosine tri phosphate; NO, nitric oxide; BH4, 
(6R)- 5,6,7,8-tetrahydro-L- biopterin; SR, Sepiapterin reductase; PTS, 6-Pyruvoyl 
tetrahydrobiopterin synthase. The sign (+) denotes activation of the reaction and the sign 
(-) denotes inhibition of the reaction.  
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Induction of diabetes with STZ injection in Sprague Dawley rats resulted in 
decreased levels of plasma [arginine] (67). Results of this study also indicated a decrease 
in plasma arginine levels in control ZDF rats. Impaired arginine synthesis and/or 
increased arginine degradation may contribute to low levels of circulating arginine in 
diabetic rats. Whatever the mechanism, arginine supplementation was effective to 
increase plasma [arginine] in both rat models of diabetes. Similarly, other researchers 
have reported decreases in plasma concentrations of arginine in experimental diabetic 
animals (10,11,12) and in diabetic humans (21,22). Thus, reduced plasma levels of 
arginine in diabetic subjects provide a metabolic basis for dietary arginine 
supplementation to diabetics. 
The “arginine paradox” has been a major conundrum in the NO research field 
over the past decade. Intracellular values of L-arginine (0.49 mM in SD rats; 0.70 mM in 
ZDF rats) in control diabetic rats were ~150 to 250 fold higher than the Km value of 
eNOS (2.9 mM) for L-arginine. Thus, on the basis of kinetics of the purified NOS in the 
test tube, an increase in intracellular or extracellular concentration of L-arginine would 
not provide more substrate for NO synthesis because eNOS should be saturated with 
arginine at levels of 0.49 or 0.70 mM. However, interactions of cellular substrates and 
cofactors with an enzyme in cells are likely more complex than in vitro enzyme 
reactions would indicate. Findings of this study provide the first line of evidence 
showing that dietary supplementation of L-arginine increases NO production in coronary 
EC of both STZ-diabetic SD rats and Zucker rats. This data further supports the notion 
that extracellular arginine concentrations are critical for endothelial NO production.  
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A central hypothesis of this thesis work is that dietary L-arginine 
supplementation increases the availability of BH4 for NO synthesis in EC of diabetic 
rats, thereby preventing endothelial dysfunction. Results of the present study confirm 
and extend the earlier findings from our laboratory that STZ-diabetic rats and ZDF rats 
exhibit low levels of BH4 in EC. To our knowledge, this is the first report of the effect of 
dietary arginine supplementation on increasing endothelial BH4 availability in both STZ-
diabetic SD rats and ZDF rats. Meininger et al. (13) reported that EC from the 
spontaneously diabetic BB rat have a deficiency of BH4 and replenishing BH4 levels in 
the EC from diabetic animals restores their ability to make NO. As a result of an increase 
in BH4 availability, administration of L-arginine restored the ability of EC to make NO 
in both STZ and ZDF diabetic rat models. Collectively, our results demonstrate that L-
arginine improves endothelial function in diabetic subjects through enhancing the 
availability of BH4 for NO synthesis by eNOS. 
Our findings with diabetic rats may have important implications for reducing 
body fat in both farm animals and humans. For example, dietary arginine 
supplementation may provide a means to decrease abdominal, back and intramuscular 
fat in pigs and poultry, thereby increasing lean tissue content. Likewise, dietary arginine 
supplementation may be extremely beneficial for obese patients. Obesity is a major 
public health problem in the U.S. and worldwide. Recent data show that 31 % and 65 % 
of the U.S. adult population are obese and overweight, respectively (74). Children and 
adolescents have not been immune to this epidemic, as 15 % of them are obese (74). 
Worldwide, more than 300 million adults are obese and over one billion are overweight 
   
 
64 
 
 
 
 
(74). Obesity is a major risk factor for such life-threatening diseases as type-II diabetes, 
atherosclerosis, hypertension, and some types of cancer (including colon and breast 
cancers). Consequently, obesity claims an increasing number of lives and contributes to 
tremendous costs of medical care. In the U.S. alone, about 300,000 people die of 
obesity-related diseases every year; incidence of type-II diabetes among children has 
increased 10-fold, and obesity accounts for 6-8 % of all health care expenditures (74,75). 
Unfortunately, clinicians have few tools to fight the obesity epidemic, because current 
antiobesity drugs are not highly effective and are fraught with side effects (76). 
Identifying arginine supplementation as a new means to reduce body fat will be 
extremely beneficial.  
 
Summary 
This research focuses on the beneficial roles of dietary L-arginine 
supplementation in diabetic rats. Specifically, we evaluated the effects of dietary L-
arginine intervention on 1) body weight, 2) plasma concentrations of glucose, insulin 
and arginine, 3) concentrations of arginine and BH4 in EC, and 4) NO synthesis in EC in 
two rat models of diabetes: STZ-diabetic rats (an animal model for type-I diabetes) and 
ZDF rats (an animal for type-II diabetes). Our results demonstrate that oral 
administration of arginine is beneficial for both STZ and ZDF diabetic rats and has no 
adverse effects in non-diabetic rats. Dietary arginine supplementation increased plasma 
concentrations of arginine as well as concentrations of arginine and BH4 in EC, and NO 
synthesis in EC, in both STZ-diabetic and non-diabetic SD rats, and in ZDF rats. 
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Additionally, arginine supplementation ameliorates weight loss in STZ diabetic rats, and 
promotes weight loss in ZDF rats. Thus, we expect that dietary arginine supplementation 
will be beneficial for diabetic subjects.  
The key findings of the present work are as follows: 
1. In STZ-diabetic SD rats, L-arginine supplementation for 2 weeks increased 
plasma concentrations of arginine (110%), plasma concentrations of insulin 
(209%), and arginine concentrations (173%), BH4 concentrations (128%), and 
NO synthesis (125%) in EC, compared with alanine-treated rats. 
2. In STZ-diabetic SD rats, L-arginine supplementation reduced body weight loss 
(36%) and prevented hyperglycemia. 
3. In non-diabetic SD rats, L-arginine treatment increased plasma concentrations of 
arginine (144%), plasma concentrations of insulin (44%), and arginine 
concentrations (88%), BH4 concentrations (106%) and EC NO synthesis (80%) 
in EC, compared with alanine-treated rats.  
4. Arginine supplementation for 10 weeks did not affect plasma levels of glucose 
and insulin in ZDF rats, compared with alanine-treated ZDF rats.  
5. In ZDF rats, supplementation with L-arginine for 10 weeks reduced epididymal 
fat (30%), abdominal fat (43%) and body weight gain (18%). 
6. Treatment with L-arginine in ZDF rats increased plasma concentrations of 
arginine (273%), and arginine concentration (197%), BH4 concentrations (120%) 
and NO production (122%) in EC by more than two folds, as compared with 
alanine-treated ZDF rats.  
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Results of this thesis work may have important implications for both animal 
agriculture and human health. Future studies are necessary to determine whether 
dietary arginine supplementation can reduce body fat in farm animals (e.g. pigs and 
chicks), companion animals (e.g. dogs and cats), and obese humans.  
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